In multiple myeloma, therapeutic strategies should focus on reversing the tumor-supportive phenotype of mesenchymal stem cells, potentially via targeted inhibition of IL-6 or CXCL12 signaling. The gene discussed is CXCL12; the disease is plasma cell myeloma.